Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anti-t-lymphocyte globulin (rabbit) (Neovii Pharmaceuticals)
- Development stage
- Unknown
- Lead developer
- Neovii Pharmaceuticals
- Modality
- Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
IIT-ATLG-64 refers to a clinical development program by Neovii Pharmaceuticals involving **anti-t-lymphocyte globulin (rabbit)**, commercially known as **Grafalon**. Grafalon is a rabbit-derived polyclonal antibody preparation directed against a broad spectrum of human T-lymphocyte surface antigens. Its primary mechanism of action involves the depletion of peripheral T-lymphocytes through complement-dependent cytotoxicity and opsonization, as well as the modulation of T-cell function and induction of apoptosis in activated T-cells. The IIT-ATLG-64 program is specifically focused on the use of this agent in the context of **stem cell transplantation (SCT)**, particularly for the prophylaxis of graft-versus-host disease (GvHD). The designation "IIT" indicates that this specific development path is being pursued through an investigator-initiated trial framework supported by Neovii, with the program currently listed in Phase 3 for SCT indications.
- Brand names
- Grafalon
- Other names
- anti-human T-lymphocyte globulin (rabbit)ATG-Fresenius
02
Targets
CD2 (T-cell Surface Antigen CD2)CD3 (T-cell surface glycoprotein CD3)CD4 (T lymphocyte surface antigen)CD8A (CD8 alpha/beta Coreceptor)IL-2RA (Interleukin-2 receptor subunit alpha)LFA-1 (Integrin αLβ2)IL2RA (Interleukin-2 receptor alpha subunit)CD45RA (T-cell surface glycoprotein CD45 isoform RA)
Beyond the preview
Go deeper on anti-t-lymphocyte globulin (rabbit) (Neovii Pharmaceuticals).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anti-t-lymphocyte globulin (rabbit) (Neovii Pharmaceuticals).